PUBLISHER: GlobalData | PRODUCT CODE: 1879796
PUBLISHER: GlobalData | PRODUCT CODE: 1879796
Bio/Pharmaceutical Outsourcing Report, October 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for -
- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter's M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
Table of Contents
Industry Trends
Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing
Trump Administration Announce Third MFN Agreement, With EMD Serono, and Includes Use of New FDA Voucher
Lower price on fertility treatments
Trump says the price of Ozempic will be lowered
Outlook and implications
Industry Analysis
Contract service agreements
Contract manufacturing - opportunities and threats
Quarterly mergers, acquisitions, and financing - Q3 2025
Value Chain
API chemical
API biologics - cell, gene, vaccine, and virus
API Biologics (Protein and Peptide)
Commercial dose manufacturing and packaging
Analytical services
About GlobalData
About the Authors
Contact Us
List of Table
List of Tables
- Table 1: Contract service agreements
- Table 2: Contract manufacturing: opportunities and threats - potentially positive
- Table 3: Contract manufacturing: opportunities and threats - potentially negative
- Table 4: Mergers, acquisitions, and fin
List of Figure
List of Figures
- Figure 1: Contract service agreements by deal geography, by volume
- Figure 2: Deals by deal geography, by volume
- Figure 3: The contract manufacturing value chain
